Microvascular Therapeutics Recognized with People’s Choice Award at the American Society of Echocardiography’s Shark Tank Competition

Nashville, TN – September 6, 2025 – Microvascular Therapeutics (MVT), a pioneering Utah-based biotechnology company, is honored to have received the People’s Choice Award at the American Society of Echocardiography (ASE) Shark Tank Competition. In addition, MVT research collaborator Dr. Soheb Anwar Mohammed, PhD, was named a Top Early Investigator by the ASE Foundation.

Dr. Soheb Anwar Mohammed Honored as Top Investigator

The ASE Foundation recognized Dr. Mohammed, a Research Assistant Professor at The University of Pittsburgh, as a Top Early Investigator for his outstanding contributions to cardiovascular research. His selection was based on the scientific merit of his work with MVT’s novel therapies. As part of this award, he received a $1,000 travel grant to support his attendance at the ASE conference and a presentation of his award in a main session.

This recognition underscores both Dr. Mohammed’s leadership as an emerging researcher and the promise of MVT’s next-generation ultrasound-based therapeutics.

“Receiving 80% of the 127 votes cast is a strong endorsement of our vision,” said Dr. Evan Unger, CEO of MVT. “We are deeply honored by this Peoples’ Choice Award from leading echocardiographers, scientists, and physicians. In addition, Dr. Mohammed’s recognition as a Top Investigator further validates that we are working with exceptional scientific talent to advance new ultrasound-based treatments for myocardial microvascular obstruction.”

“I am truly grateful for this recognition from my peers,” said Dr. Mohammed. “Leading this research alongside MVT gives me immense pride. We believe ultrasound-based therapies hold tremendous potential to transform the treatment of microvascular obstruction and address  a critical unmet medical need.”

About MVT: MVT was founded to transform ultrasound from diagnosis to cure. In the 1990’s, the founder of MVT developed Perflutren the world’s #1 selling ultrasound contrast agent. MVT finished Phase II clinical trials of MVT-100, a new ultrasound contrast agent with potential to eliminate side effects and improve diagnostic performance. Based on MVT-100, the Company has also developed theranostic products with breakthrough potential in treatment of vascular disease and cancer.

Media Contact: Bryan Unger

Microvascular Therapeutics, INC

P.O. Box 8089, Alta, UT 84092

Email: b.unger@mvtpharma.com

Phone: (520) 555-1234

About Microvascular Therapeutics (MVT):Microvascular Therapeutics is a biotechnology company focused on developing next-generation microbubble-based therapies for cardiovascular and other diseases. Its proprietary fibrin-targeted phase-shift microbubbles (FTPSMBs) leverage ultrasound-targeted microbubble cavitation (UTMC) to address critical conditions such as myocardial microvascular obstruction, aiming to improve patient outcomes worldwide.

Investor Disclaimer: This press release contains forward-looking statements that involve risks and uncertainties, including statements regarding the potential efficacy and future development of Microvascular Therapeutics’ therapies, such as fibrin-targeted phase-shift microbubbles (FTPSMBs) and sonoreperfusion (SRP) therapy. These statements are based on current expectations and assumptions and are subject to significant risks and uncertainties that could cause actual results to differ materially from those anticipated. These risks include, but are not limited to, challenges in clinical development, regulatory approvals, market acceptance, and funding availability. Microvascular Therapeutics undertakes no obligation to update or revise any forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. For more detailed information on risks and uncertainties, please contact Microvascular Therapeutics directly.